Table 5 Costs of management of adverse events attributed to chemotherapy
National tariff | ENCC | Adjusted ENCC | |
|---|---|---|---|
All ADRs – Annual per capita costs | |||
Pre-progression (N = 1223 patients) | |||
Base case | € 3729 | € 3947 | € 3915 |
Survival-corrected | € 3979 | € 4212 | € 4177 |
Post-progression (N = 1354 patients) | |||
Base case | € 5474 | € 5452 | € 5631 |
Survival-corrected | € 8582 | € 8546 | € 8827 |
Individual ADRs (both progression stages combined) – Mean cost per stay with ADRa | |||
Infections (N = 1090 stays) | € 3936 ± 4328 | € 4184 ± 4301 | € 4214 ± 4451 |
Neutropenia (N = 225 stays) | € 3806 ± 3920 | € 4115 ± 3877 | € 3946 ± 3988 |
Glomerulonephritis (N = 41 stays) | € 3456 ± 3552 | € 3713 ± 4099 | € 3698 ± 4017 |
Myalgia/pain (N = 309 stays) | € 3032 ± 4609 | € 2580 ± 2213 | € 2940 ± 4468 |
Colitis (N = 93 stays) | € 2942 ± 2114 | € 3107 ± 2078 | € 3105 ± 2130 |
Diarrhoea (N = 40 stays) | € 2747 ± 3036 | € 3043 ± 4158 | € 3104 ± 4376 |
Decreased blood ACTH (N = 34 stays) | € 2607 ± 2725 | € 2410 ± 1907 | € 2454 ± 2143 |
Fatigue (N = 268 stays) | € 2567 ± 2817 | € 2405 ± 1771 | € 2541 ± 2549 |
Skin reactions (N = 137 stays) | € 2333 ± 2544 | € 2278 ± 1647 | € 2398 ± 2514 |
Dyspnoea (N = 56 stays) | € 1875 ± 1508 | € 1896 ± 1487 | € 1918 ± 1512 |
Anaemia (N = 660 stays) | € 1645 ± 2510 | € 1726 ± 1554 | € 1791 ± 2370 |
Nausea/vomiting (N = 42 stays) | € 1302 ± 703 | € 1539 ± 796 | € 1532 ± 792 |
Thrombocytopenia (N = 208 stays) | € 1252 ± 1432 | € 1929 ± 2159 | € 1392 ± 1330 |
Basocellular carcinoma (N = 2599 stays) | € 1129 ± 2671 | € 1073 ± 1922 | € 1116 ± 2553 |
Neuropathies (N = 15 stays) | € 691 ± 597 | € 1489 ± 610 | € 808 ± 586 |